Endosense, a medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation, has announced that it has received USD 36 million in Series B financing.
Cardio
Boston Scientific Corporation announces long-term data from the Prevention of Sudden Cardiac Death II registry (PreSCD II)
Boston Scientific Corporation’s PreSCD II Registry Shows ICDs Lead to 44 Percent Reduction in Mortality for Heart Attack Survivors.
Abbott Launches Next-Generation XIENCE PRIME™ Drug Eluting Stent in International Markets
Abbott today announced at the European Society of Cardiology Congress the widespread availability of its next-generation XIENCE PRIME™ Everolimus Eluting Coronary Stent System.
TomTec Extends the CardioArena Product Portfolio with a Vascular Analysis Solution
TomTec launches the vascular analysis solution M’Ath®1 as a further part of their CardioArena™ multimodality imaging program at the European Society of Cardiology congress 2009 in Barcelona.
MAQUET Cardiovascular Launches VASOVISION Endoscopic Visualization System to Further Advance Vessel Harvest During Coronary Bypass Surgery
MAQUET Cardiovascular LLC today announced the introduction of the VASOVISION Endoscopic Visualization System, a heads-up, goggle-based visual display system.
CryoLife Receives FDA 510(k) Clearance For SynerGraft® Processed Human Cardiac Patch Material
CryoLife, Inc. announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its CryoPatch(®) SG pulmonary human cardiac patch.
Total Artificial Heart Bridges People Rejecting Donor Hearts To 2nd Transplant
During 2008, 10% of people who were implanted with the SynCardia temporary CardioWest™ Total Artificial Heart received the device because they were suffering from rejection of their donor heart transplant.
Onset Medical Receives European CE Mark Approval for the SoloPath Endovascular Access Catheter
Onset Medical Corporation announced today the Company has received CE Mark approval to begin marketing the Company’s SoloPathTM Endovascular Access Catheter in the European Union.
Atrium Medical Corporation Announces Release of the Interim Results of the “COCTAIL Study”
Atrium Medical Corporation is proud to announce the release of the interim results of the “COCTAIL Study.”
Spectranetics Announces First Human Uses of Turbo-Tandem System
Spectranetics Corporation today reported the first human procedures using its Turbo-Tandem™ System, which had earlier received FDA clearance and CE mark approval for marketing in the US and the EU.
CardioFocus Receives CE Mark For Atrial Fibrillation Ablation Catheter
CardioFocus, Inc. announced that it has received a CE Mark allowing the company to commence European marketing of the Endoscopic Ablation System (EAS) to treat patients with atrial fibrillation.
Study Finds Edwards Lifesciences’ Port Access System Facilitates Improved Outcomes Compared to Sternotomy
Edwards Lifesciences Corporation announced that new research demonstrates that using its minimally invasive PORT ACCESS System in mitral valve surgery significantly improves outcomes when compared to conventional sternotomy.
New Data Proves Effectiveness Of Medtronic Insertable Cardiac Monitor In Detecting AF
Data presented today at the EUROPACE 2009 congress on the XPECT clinical trial, sponsored by Medtronic, Inc., shows positive results for the Medtronic Reveal® XT Insertable Cardiac Monitor (ICM).
Sorin Group Announces European Market Release and First Implant of Its New-Generation Dual Chamber Implantable Cardioverter Defibrillator
Sorin Group announced today the commercial market release and first implant of its new generation PARADYM™ DR 8550 dual chamber implantable cardioverter-defibrillator (ICD).
CorNova® Receives CE Mark Approval For Valecor Platinum® Coronary Stent System
CorNova Inc. announced that it has received CE mark approval for its Valecor Platinum Coronary Stent System.
New Therapy Found To Prevent Heart Failure
A landmark study has successfully demonstrated a 29 percent reduction in heart failure or death in patients with heart disease who received an implanted cardiac resynchronization therapy device with defibrillator versus patients who received only an implanted cardiac defibrillator.